RxDoctor Payments Data

Qiu Tong, MD

Cardiovascular Disease · Batavia, NYNPI 1275055386

Payments from drug & device makers

$1,262in general payments, 2019–2025

Across 60 payments — averaging $21.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$317
  • AstraZeneca$136
  • Pfizer$87
  • Novo Nordisk$84
  • Boehringer Ingelheim$78
  • Kestra Medical Technology Services, Inc.$77
  • plus $482 from 13 others

What the payments were for

  • Food & beverage$1,262100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,262 in reported general payments places this provider in the 45th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$31,779
Medicare patients
228
Services billed
435

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin133$154,551
EliquisApixaban90$124,488
EntrestoSacubitril/Valsartan68$87,691
FarxigaDapagliflozin Propanediol26$31,774
Repatha SureclickEvolocumab31$27,597
XareltoRivaroxaban23$25,465
BrilintaTicagrelor21$25,190
VascepaIcosapent Ethyl29$12,518
Rosuvastatin Calcium262$4,587
Ezetimibe117$3,782
Metoprolol Succinate221$3,551
Atorvastatin Calcium228$2,880
Eplerenone26$2,521
Amlodipine-ValsartanAmlodipine Besylate/Valsartan33$1,982
Carvedilol180$1,684

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$78$154,551133 claims
PfizerEliquis$87$124,48890 claims
NovartisEntresto$317$87,69168 claims
AstraZenecaFarxiga, Brilinta$136$56,96547 claims
Johnson & JohnsonXarelto$38$25,46523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Batavia

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →